AtriCure Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG
July 31, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $53.00 (from $58.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q2 revenue of $116.3M (+15.2% y/y rep, +15.4% y/y cc), in line with consensus of $116.2M. U.S. Q2 revenue was $95.5M (+12.5% y/y), lower than consensus of $97.1M, while International revenue of $20.7M (+29.4% y/y rep, +30.4% y/y cc) beat consensus of $19.0M. The U.S. Appendage Management segment reported $37.9M (+11.8% y/y) in Q2 sales, missing consensus of $38.3M by $400K. However, growth in... More
